DE69735581T2 - Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung - Google Patents

Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung Download PDF

Info

Publication number
DE69735581T2
DE69735581T2 DE69735581T DE69735581T DE69735581T2 DE 69735581 T2 DE69735581 T2 DE 69735581T2 DE 69735581 T DE69735581 T DE 69735581T DE 69735581 T DE69735581 T DE 69735581T DE 69735581 T2 DE69735581 T2 DE 69735581T2
Authority
DE
Germany
Prior art keywords
drug
active ingredient
hours
dosage form
tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735581T
Other languages
German (de)
English (en)
Other versions
DE69735581D1 (de
Inventor
K. Suneel Sunnyvale GUPTA
R. Diane Palo Alto GUINTA
A. Carol Belmont CHRISTOPHER
R. Samuel Burlingame SAKS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69735581(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69735581D1 publication Critical patent/DE69735581D1/de
Publication of DE69735581T2 publication Critical patent/DE69735581T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69735581T 1996-09-30 1997-09-16 Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung Expired - Lifetime DE69735581T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2872696P 1996-09-30 1996-09-30
US28726P 1996-09-30
US3051496P 1996-11-12 1996-11-12
US30514P 1996-11-12
US4412197P 1997-04-22 1997-04-22
US44121P 1997-04-22
PCT/US1997/016599 WO1998014168A2 (en) 1996-09-30 1997-09-16 Dosage form providing a sustained and ascending drug release

Publications (2)

Publication Number Publication Date
DE69735581D1 DE69735581D1 (de) 2006-05-18
DE69735581T2 true DE69735581T2 (de) 2007-01-25

Family

ID=27363329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735581T Expired - Lifetime DE69735581T2 (de) 1996-09-30 1997-09-16 Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung

Country Status (11)

Country Link
EP (1) EP0932388B1 (https=)
JP (3) JP4714313B2 (https=)
CN (1) CN1231603A (https=)
AT (1) ATE321529T1 (https=)
AU (1) AU4801497A (https=)
CA (1) CA2264852C (https=)
DE (1) DE69735581T2 (https=)
DK (1) DK0932388T5 (https=)
ES (1) ES2262174T3 (https=)
PT (1) PT932388E (https=)
WO (1) WO1998014168A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2842550A1 (de) 2013-08-29 2015-03-04 KliniPharm GmbH Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
ES2262174T3 (es) * 1996-09-30 2006-11-16 Alza Corporation Forma de dosificacion y procedimiento de administracion de medicamentos.
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
PT1083879E (pt) * 1998-06-03 2005-01-31 Alza Corp Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
AU2012232984B2 (en) * 1998-06-03 2015-10-29 Alza Corporation Methods and devices for providing prolonged drug therapy
KR100827254B1 (ko) * 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
AU2004200938B2 (en) * 1998-06-03 2006-09-14 Alza Corporation Methods and devices for providing prolonged drug therapy
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US7300668B2 (en) 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
JP2010229140A (ja) * 2002-02-22 2010-10-14 Shire Llc 活性物質送達系及び活性物質を保護し投与する方法
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
JP2008509144A (ja) * 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
DK2036546T3 (en) 2004-08-23 2018-12-17 Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg Psychostimulants containing a pharmaceutical composition
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
EP1920768A1 (en) 2006-11-10 2008-05-14 Abbott GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
EP2994112A1 (en) 2013-03-29 2016-03-16 Wockhardt Limited Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
EP0094123A3 (en) * 1982-05-06 1984-07-25 THE PROCTER & GAMBLE COMPANY Therapeutic granules
EP0212747B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release and immediate release
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.
ES2262174T3 (es) * 1996-09-30 2006-11-16 Alza Corporation Forma de dosificacion y procedimiento de administracion de medicamentos.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2842550A1 (de) 2013-08-29 2015-03-04 KliniPharm GmbH Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung
DE102013014417A1 (de) 2013-08-29 2015-03-05 Klinipharm Gmbh Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
PT932388E (pt) 2006-07-31
CA2264852A1 (en) 1998-04-09
HK1127997A1 (en) 2009-10-16
DK0932388T5 (da) 2011-06-27
JP4714313B2 (ja) 2011-06-29
DK0932388T3 (da) 2006-07-17
AU4801497A (en) 1998-04-24
JP2014028854A (ja) 2014-02-13
JP5697893B2 (ja) 2015-04-08
ATE321529T1 (de) 2006-04-15
JP2001501223A (ja) 2001-01-30
DE69735581D1 (de) 2006-05-18
ES2262174T3 (es) 2006-11-16
EP0932388B1 (en) 2006-03-29
CA2264852C (en) 2005-11-01
CN1231603A (zh) 1999-10-13
WO1998014168A3 (en) 1998-07-30
JP2010195822A (ja) 2010-09-09
EP0932388A2 (en) 1999-08-04
WO1998014168A2 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
DE69735581T2 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
DE69635959T2 (de) Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme
DE69929041T2 (de) Verwendung von cabergolin zur behandlung von "restless legs syndrom"
DE69715899T2 (de) Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
DE60019436T2 (de) Verwendung von nikotin oder derivaten davon und l-dopa in einem medikament zur behandlung von neurologischen erkrankungen, insbesondere der parkinson-erkrankung
DE60115872T2 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
DE69224069T2 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE69735656T2 (de) Vorrichtung zur transdermalen Verabreichung von Fluoxetin
DE69300608T2 (de) Verwendung von L-Deprenyl zur Herstellung eines Arzneimittels zur Behandlung der Cushing's-Krankheit.
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE19737348A1 (de) Neue pharmazeutische Zusammensetzung
DE3116860C2 (https=)
EP1513533B1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
DE60117122T2 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE2758549A1 (de) Pharmazeutische zubereitung
DE19726871C1 (de) Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
DE69821970T2 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE19629802A1 (de) Arzneimittel zur Behandlung von Neuropathien
DE212018000171U1 (de) Zusammensetzung zur Verwendung in der Prävention oder Behandlung von Autismus-Spektrum-Störungen umfassend ein Salz der Benzoesäure
EP0493861B1 (de) Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel
EP4349333B1 (de) Verwendung von aminopyridin, insbesondere amifampridin, bei der behandlung einer viral assoziierten fatigue
DE3851669T2 (de) Verwendung von Gepiron für Medikamente zur Milderung panischer Zustände.
DE2144060C3 (de) Arzneimittel mit antikonvulsiver Wirkung
DE2830044A1 (de) Pharmazeutisches praeparat zur behandlung von schlafstoerungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition